

Validation study

First International Workshop on
Interim PET/CT in Lymphoma

Purpose

- To validate the results of previously published studies in HL and DLBCL
- To investigate the consensus criteria on an international cohort of lymphoma patients currently being collected
- To assess the interobserver variability using the consensus criteria

Methods

- Cases are collected retrospectively
- Patients eligible if interim PET/CT performed after 2 cycles of chemotherapy
- Patients excluded if clinical decisions are based on interim PET/CT results alone
- A baseline PET/CT is mandatory
- Only PET/CT technology allowed

Hodgkin Lymphoma

- The five-point visual assessment is applied as proposed at the Deauville consensus meeting
- A cohort of ABVD-treated advanced-stage HL patients has been collected to validate previous results
- This cohort will soon be expanded for assessment of consensus criteria, including all clinical stages of disease
- Assessment of the additional value of SUV analysis

Diffuse Large B-cell Lymphoma

- The five-point visual assessment is applied as proposed at the Deauville consensus meeting
- Assessment of the additional value of SUV analysis as proposed in the recent publication by the GELA group (Itti et al.)
- Stratified analysis according to therapy (14- vs 21-day schedules and +/- rituximab) and prognostic score (IPI)

Next steps

- May 2009: End of accrual of cases
- September 2009: All images and clinical data collected
- February 2010: End of analysis
- April 2010, Menton: First report of results

PET/CT review panel:

Barrington S, Biggi A, Hutchings M, Meignan M +
any interested colleagues from centres with
significant contribution of cases

See you in Menton (France)



Second International Workshop on Interim-PET in lymphoma

Menton, April, 9-10, 2010